Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

MLA

Mark R. Litzow, et al. “Blinatumomab Retreatment after Relapse in Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia.” Leukemia, vol. 32, no. 2, Oct. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9de9adee87174d8bb2aa626e13bd0c76&authtype=sso&custid=ns315887.

APA

Mark R. Litzow, Johannes Duell, Tanya M. Trippett, Matthias Klinger, Leonard T. Heffner, Chris Holland, Ralf C. Bargou, M Stelljes, Phillip Barnette, Jonathan Benjamin, Gerhard Zugmaier, & Max S. Topp. (2017). Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Leukemia, 32(2).

Chicago

Mark R. Litzow, Johannes Duell, Tanya M. Trippett, Matthias Klinger, Leonard T. Heffner, Chris Holland, Ralf C. Bargou, et al. 2017. “Blinatumomab Retreatment after Relapse in Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia.” Leukemia 32 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9de9adee87174d8bb2aa626e13bd0c76&authtype=sso&custid=ns315887.